Anzeige
Mehr »
Samstag, 25.10.2025 - Börsentäglich über 12.000 News
Gold über 4.000 US-Dollar - Canary Gold startet Multi-Front-Exploration in Brasiliens neuem Gold-Hotspot
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M84G | ISIN: SE0002190926 | Ticker-Symbol: 2I9
Frankfurt
24.10.25 | 08:01
0,053 Euro
+2,12 % +0,001
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KAROLINSKA DEVELOPMENT AB Chart 1 Jahr
5-Tage-Chart
KAROLINSKA DEVELOPMENT AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0680,10024.10.

Aktuelle News zur KAROLINSKA DEVELOPMENT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
KAROLINSKA DEVELOPMENT Aktie jetzt für 0€ handeln
FrKarolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines presents positive data from a preclinical study of SVF-001 in chronic hepatitis B and D1
09.10.Karolinska Development AB (publ): Karolinska Development's portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain41STOCKHOLM, SWEDEN - October 9, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company PharmNovo has received approval from the Spanish regulatory authorities...
► Artikel lesen
03.10.Karolinska Development AB (publ): Karolinska Development's portfolio company Dilafor receives patent in the US for tafoxiparin in priming of labor2
16.09.Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio completes patient recruitment in phase 2a study of its drug candidate AC011
04.09.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson's disease model1
29.08.Karolinska Development AB (publ): Interim Report - January-June 2025107STOCKHOLM - 29 August 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-June 2025. The full report is available on the Company's website. "We have...
► Artikel lesen
28.08.Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue3
14.07.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition raises MSEK 24.6 for the ongoing clinical development of golexanolone3
14.07.Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin268STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part...
► Artikel lesen
03.07.Karolinska Development AB (publ): Karolinska Development receives update from Organon concerning OG-621911
30.06.Karolinska Development AB (publ): Karolinska Development divests shares in portfolio company OssDsign321STOCKHOLM, SWEDEN, June 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests its remaining shares in the portfolio company OssDsign and thereby strengthens the investment company's...
► Artikel lesen
27.06.Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million1
04.06.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets139STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out a directed share issue through an accelerated bookbuilding...
► Artikel lesen
26.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study1
15.05.Karolinska Development AB (publ): Karolinska Development's Annual General Meeting 20252
13.05.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US2
07.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition presents data validating novel clinical scale in PBC at EASL 20251
05.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition receives grant from The Michael J. Fox Foundation266STOCKHOLM, SWEDEN - May 5, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has been awarded a research grant by The Michael J....
► Artikel lesen
30.04.Karolinska Development AB (publ): Karolinska Development portfolio company OssDsign will change CEO during second half of 20253
30.04.Karolinska Development AB (publ): Interim Report - January-March 2025143STOCKHOLM - 30 April 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-March 2025. The full report is available on the Company's website. "Developmental...
► Artikel lesen
Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1